Related Experiment Video

Updated: Jun 13, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future

Elaina M Gartner1, Angelika M Burger, Patricia M Lorusso

  • 1Departments of Internal Medicine and daggerPharmacology, Karmanos Cancer Institute at Wayne State University, Detroit, MI 48201, USA.

Cancer Journal (Sudbury, Mass.)
|April 21, 2010
PubMed

Insights

Poly(ADP-ribose) polymerase inhibitors are novel antineoplastic agents that enhance cancer therapy by blocking DNA damage repair. They show promise in BRCA-mutated cancers and when combined with chemotherapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Poly(ADP-ribose) polymerase (PARP) inhibitors represent a new class of anticancer drugs.
  • These agents disrupt cellular DNA damage repair mechanisms.
  • PARP inhibitors are particularly effective in cancers with existing DNA repair deficiencies, like BRCA mutations, or when used with DNA-damaging chemotherapy.

Purpose of the Study:

  • To review the development and laboratory background of PARP inhibitors.
  • To discuss the rationale behind biologic correlative studies in clinical trials.
  • To present recent clinical trial data and ongoing studies of specific PARP inhibitors.

Main Methods:

  • Review of preclinical and clinical research on PARP inhibitors.
  • Analysis of biologic correlative studies in clinical trials.
  • Presentation of data from clinical trials involving olaparib, BSI-201, AG014699, ABT-888, and INO-1001.

Main Results:

  • PARP inhibitors impair cellular recovery from DNA damage.
  • Clinical trials are evaluating the efficacy of various PARP inhibitors.
  • Specific agents like olaparib are showing promise in ongoing studies.

Conclusions:

  • PARP inhibitors are a significant advancement in cancer treatment.
  • Their efficacy is linked to DNA repair defects and combination chemotherapy.
  • Further clinical studies are essential to define their role in oncology.

More Related Videos

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses11:34

High-throughput Screening for Broad-spectrum Chemical Inhibitors of RNA Viruses

Published on: May 5, 2014

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...